Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
👨⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RecruitingNCT06899581 ↗
Gut Health in Children With Cancer
🏥 Great Ormond Street Hospital for Children NHS Foundation Trust📍 1 site📅 Started Jan 2025View details ↗
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
👨⚕️ Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Jan 2025View details ↗
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
👨⚕️ Seth E. Karol, MD, MSCI, St. Jude Children's Research Hospital📍 3 sites📅 Started Dec 2024View details ↗
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
👨⚕️ Seth E. Karol, MD, St. Jude Children's Research Hospital📍 3 sites📅 Started Dec 2024View details ↗
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
👨⚕️ Annie P Im, University of Pittsburgh Cancer Institute LAO📍 4 sites📅 Started Dec 2024View details ↗
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Nov 2024View details ↗
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
RecruitingNCT06692894 ↗
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →